Fulgent Genetics Secures $99M in Funding to Revolutionize Diagnostics and Therapeutics

Fulgent Genetics, a pioneering leader in genomic testing since its inception in 2011, has successfully raised $99 million in a recent funding round to further its mission of developing flexible and affordable diagnostics and therapeutics that enhance the everyday lives of patients. Renowned for its innovative technology platform, Fulgent specializes in a comprehensive range of genomic testing services that encompass oncology, anatomic pathology, infectious and rare diseases, and reproductive health. This significant investment will fuel Fulgent's expansion and enhance its capabilities in delivering high-quality, accessible care. The company is poised to utilize these funds to advance its cutting-edge offerings, including Fulgent Oncology, Fulgent BioPharma, and specialized products like HelioLiver, all designed to redefine patient management for clinicians and patients alike. With a commitment to excellence, Fulgent operates as a CLIA-certified and CAP-accredited laboratory, ensuring that patients receive the highest standards of care. By investing in innovative genomic solutions, Fulgent Genetics is not just transforming the diagnostics landscape; it is shaping the future of healthcare by empowering patients and healthcare providers with actionable insights. With this new capital, Fulgent is determined to enhance its testing menu further, innovate its service offerings, and ultimately improve patient outcomes on a broader scale. As the company continues on its journey towards redefining medicine, it stands at the forefront of a genomic revolution, dedicated to making healthcare more effective and personalized for everyone.